{
  "id" : "extension_bci",
  "algorithm" : "eod_public",
  "version" : "2.1",
  "name" : "EOD Primary Tumor",
  "title" : "EOD Primary Tumor",
  "notes" : "**Note 1:** The following histologies can be localized (code 100), systemic (700) or unknown (999) \n\n9740 Mast cell sarcoma \n9749 Erdheim-Chester disease (2021+ only)\n9751 Langerhans cell histiocytosis, disseminated \n9755 Histiocytic sarcoma \n9756 Langerhans cell sarcoma \n9757 Interdigitating dendritic cell sarcoma \n9758 Follicular dendritic cell sarcoma \n9759 Fibroblastic reticular cell tumor\n9930 Myeloid sarcoma \n9971 Polymorphic PTLD (2018-2020 only, nonreportable as of 2021)\n\n**Note 2:** For histologies listed in **Note 1**, it is possible to have lymph node involvement; however, at this time, lymph node involvement for these histologies is not collected.\n\n**Note 3:** **The following histologies are systemic (code 700):**\n\n9591 Splenic B-cell lymphoma/leukemia, unclassifiable\n9724 Systemic EBV-positive T-cell lymphoma of childhood\n9727 Blastic plasmacytoid dendritic cell neoplasm\n9741 Systemic mastocytosis with an associated hematological neoplasm\n9742 Mast cell leukemia\n9762 Heavy chain diseases\n9800 Leukemia, NOS\n9801 Acute undifferentiated leukemia\n9806 Mixed-phenotype acute leukemia with t(9;22)(q34.1;q11.2); *BCR-ABL1*\n9807 Mixed-phenotype acute leukemia with t(v;11q23.3); *KMT2A*-rearranged\n9808 Mixed -phenotype acute leukemia, B/myeloid, NOS\n9809 Mixed-phenotype acute leukemia, T/myeloid, NOS\n9811 B-lymphoblastic leukemia/lymphoma, NOS\n9812 B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2); *BCR-ABL1*\n9813 B-lymphoblastic leukemia/lymphoma with t(v;11q23.3); *KMT2A*-rearranged\n9814 B-lymphoblastic leukemia/lymphoma with t(12;21)(p13.2;q22.1); *ETV6-RUNX1*\n9815 B-lymphoblastic/lymphoma with hyperdiploidy\n9816 B-lymphoblastic/lymphoma with hypodiploidy (hypodiploid ALL)\n9817 B-lymphoblastic/lymphoma with t(5;14)(q31.1;q32.1); IGH/*IL3*\n9818 B-lymphoblastic/lymphoma with t(1;19)(q23;p13.3); *TCF3-PBX1*\n9819 B-lymphoblastic leukemia/lymphoma, BCR-ABL1-like (2021+ only)\n9820 Lymphoid leukemia, NOS\n9831 T-cell large granular lymphocytic leukemia\n9832 Prolymphocytic leukemia, NOS\n9833 B-cell prolymphocytic leukemia\n9834 T-cell prolymphocytic leukemia\n9837 T-lymphoblastic leukemia/lymphoma \n9840 Pure erythroid leukemia\n9860 Myeloid leukemia, NOS\n9861 Acute myeloid leukemia, NOS\n9863 Chronic myeloid leukemia\n9865 Acute myeloid leukemia with t(6;9)(p23;q34.1); *DEK-NUP214*\n9866 Acute promyelocytic leukemia with *PML-RARA*\n9867 Acute myelomonocytic leukemia\n9869 Acute myeloid leukemia with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26;2); *RBM15-MKL1*\n9870 Acute basophilic leukemia\n9871 Acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); *CBFB-MYH11*\n9872 Acute myeloid leukemia, minimal differentiation\n9873 Acute myeloid leukemia without maturation\n9874 Acute myeloid leukemia with maturation\n9875 Chronic myeloid leukemia, *BCR-ABL1*-positive\n9876 Atypical chronic myeloid leukemia *BCR-ABL1*-negative\n9877 Acute myeloid leukemia with mutated NPM1 (2021+ only)\n9878 Acute myeloid leukemia with biallelic mutation of CEBPA (2021+ only)\n9879 Acute myeloid leukemia with mutated RUNX1 (2021+ only)\n9891 Acute monoblastic and monocytic leukemia\n9895 Acute myeloid leukemia with myelodysplasia-related changes\n9896 Acute myeloid leukemia with t(8;21)(q22;q22.1), *RUNX1-RUNX1T1*\n9897 Acute myeloid leukemia with t(9;11)(p21.3;q23.3); *KMT2A-MLLT3*\n9898 Myeloid leukemia associated with Down Syndrome\n9910 Acute megakaryoblastic leukemia\n9911 Acute myeloid leukemia (megakaryoblastic) with t(1;22)(p13.3;q13.1); *RBM15-MKL1*\n9912 Acute myeloid leukemia with BCR-ABL1 (2021+ only)\n9920 Therapy-related myeloid neoplasms\n9931 Acute panmyelosis with myelofibrosis\n9940 Hairy cell leukemia\n9945 Chronic myelomonocytic leukemia, NOS\n9946 Juvenile myelomonocytic leukemia\n9948 Aggressive NK-cell leukemia\n9950 Polycythemia vera\n9961 Primary myelofibrosis\n9962 Essential thrombocythemia\n9963 Chronic neutrophilic leukemia\n9964 Chronic eosinophilic leukemia, NOS\n9965 Myeloid/lymphoid neoplasms with *PDGFRA* rearrangement\n9966 Myeloid/lymphoid neoplasm with *PDGFRB* rearrangement\n9967 Myeloid/lymphoid neoplasm with *FGFR1* rearrangement\n9968 Myeloid/lymphoid neoplasm with PCM1-JAK2 (2021+ only)\n9975 Myelodysplastic/myeloproliferative neoplasm, unclassifiable\n9980 Myelodysplastic syndrome with single lineage dysplasia\n9982 Myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia\n9983 Myelodysplastic syndrome with excess blasts\n9985 Myelodysplastic syndrome with multilineage dysplasia\n9986 Myelodysplastic syndrome with isolated del(5q)\n9989 Myelodysplastic syndrome, unclassifiable\n9991 Refractory neutropenia (2018-2020 only, see code 9980/3 for 2021+)\n9992 Refractory thrombocytopenia (2018-2020 only, see code 9980/3 for 2021+)\n9993 Myelodysplastic syndrome with ring sideroblasts and multilineage dysplasia (2021+ only)",
  "footnotes" : "(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998\n\n(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.\n\n(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05**. American Joint Committee on Cancer (Chicago, IL)\n\n(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(5) **Introduction to Hematologic Malignancies**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017\n\n(6) Radich, J.P., Jaffe, E.S., Leonard, J.P., et al. **Leukemia**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017",
  "last_modified" : "2021-04-08T19:00:18.719Z",
  "definition" : [ {
    "key" : "eod_primary_tumor",
    "name" : "Code",
    "type" : "INPUT"
  }, {
    "key" : "description",
    "name" : "Description",
    "type" : "DESCRIPTION"
  }, {
    "key" : "eod_2018_t",
    "name" : "EOD 2018 T",
    "type" : "ENDPOINT"
  }, {
    "key" : "ss2018_t",
    "name" : "SS2018 T",
    "type" : "ENDPOINT"
  } ],
  "rows" : [ [ "100", "Localized disease\n(Single/solitary/unifocal/isolated)\n\nSee Notes 1 and 2", "VALUE:88", "VALUE:L" ], [ "700", "Systemic disease\n\nSee Note 3", "VALUE:88", "VALUE:D" ], [ "999", "Unknown; extension not stated\nPrimary tumor cannot be assessed\nNot documented in medical record\n\nDeath Certificate Only", "VALUE:88", "VALUE:U" ] ]
}